In this investigation, we have generated a tetravalent anti-EGFR/VEGFR2 BsAb with IgG-like format, which has ability to simultaneously block EGFR and VEGFR2 signaling pathways and demonstrate superior anti-tumor activity in vitro and in vivo models on TNBC. This evidence concerns the gene KDR and neoplasm.